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osting by EAbstract Depending on the clinical findings, the infertile male patient needs genetic evaluation.
Karyotype analysis and Y-chromosomal microdeletion screening should be performed in patients
with azoospermia or severe oligozoospermia in order to rule out structural chromosomal abnormal-
ities, Klinefelter syndrome and Y chromosome microdeletions. Infertile patients with obstructive
azoospermia need cystic fibrosis transmembrane receptor gene screening, while in patients with
hypogonadotropic hypogonadism mutation screening may be performed according to clinical fea-
tures. All genetic analyses should be accompanied by expert counseling by a clinical genetist both in
male and female patients.
Primary amenorrhea should be investigated by karyotype analysis and selected mutation screen-
ing according to the patient’s clinical features. Karyotype analyses and FMR1 gene screening is rec-
ommended in cases of POF. At present the infertility of patients with POF cannot be restored if the
diagnosis is made after complete follicular depletion, but in some cases, early diagnosis by genetic
investigation may instead lead to the advice of early conception or oocyte harvesting and preserva-
tion. In addition, the accumulation and annotation of array comparative genomic hybridization
data might, in the near future, lead to the identification of pathogenetic copy number variations
and genes involved in POF. Karyotype analysis of both partners is recommended in all couples with
recurrent pregnancy loss. No routine genetic test can be recommended so far in patients with PCOS.
 2010 Middle East Fertility Society. Production and Hosting by Elsevier B.V. All rights reserved.re.it (M. Simoni).
lity Society. Production and
reserved. Peer-review under
ociety.
lsevier1. Introduction
Infertility is a disease of the reproductive system defined by the
failure to achieve a clinical pregnancy after 12 months or more
of regular unprotected sexual intercourse. Of all couples clas-
sified as infertile, female infertility accounts for about 40–
50%. In 30–40% of infertile couples, male infertility is the
cause, while the remaining 10–30% either is attributed to both
male and female infertility or is unexplained (1) (Fig. 1).
Figure 1 Causes of couple infertility. The male data are taken from Simoni et al. (2).
140 E. Kara, M. Simoni1.1. Male infertility
In the male the fertility criteria include: normal spermatogen-
esis, complete maturation of the spermatozoa during the
passage through the accessory organs of the reproductive sys-
tem, accessory organs’ patency, production of an adequate
volume of seminal fluid, ability to deposit the semen into the
vagina, mobility of the spermatozoa adequate to reach the oo-
cyte in the uterine tubes and penetrate it (3).
Currently, a discrete genetic cause can be demonstrated in
over 20% of patients presenting with azoospermia and severe
oligozoospermia who are obligatory candidates for genetic
screening (own, unpublished data).
Among the best-known and most frequent genetic causes of
male infertility are chromosomal abnormalities, mutations of
the cystic fibrosis transmembrane receptor gene (CFTR) and
Y chromosome microdeletions (4). Studies on families of infer-
tile patients suggest that male infertility may have a familial
component and an autosomal-recessive mechanism of inheri-
tance was suggested (5,6).
The main indications for genetic testing in male infertility
are azoospermia and severe oligozoospermia upon semen anal-
ysis (4). Even if detection of a genetic alteration will not sub-
stantially change the treatment, genetic testing should be
performed for two reasons: to finalize a causal diagnosis;
and to asses the genetic risk for the offspring in case of success-
ful treatment. Expert counselling by a clinical geneticist should
accompany every genetic test (4).
1.1.1. Chromosomal abnormalities
Numerical and structural chromosomal aberrations can be
determined by karyotype analysis. The prevalence of chromo-
somal aberrations in infertile men is known to be around
10–15 times higher than in the general population, and ranges
between 2% and 16% with an increasing frequency of abnor-
malities of autosomes with decreasing sperm count (Table 1)
(8–10).
In the majority of cases, the infertile patient is an otherwise
healthy male (apart from syndromic cases) and the chromo-somal anomaly does not play any pathological role. However,
men carrying a translocation, for example, have a markedly in-
creased risk of inducing a pregnancy ending in miscarriage/
stillbirth or fathering a child with varying degrees of mental
and/or physical retardation in case of an unbalanced chromo-
some set of the offspring (4). Therefore, karyotype analysis is
indicated in every infertile man with oligo- or azoospermia
and, at least in cases of an abnormal karyotype, should be
accompanied by genetic counselling.
1.1.2. Klinefelter syndrome
Men with Klinefelter syndrome (karyotype 47, XXY including
mosaics) are common among infertile patients and may be
identified by the following clinical features (11): reduced testic-
ular volume (usually <6 bitesticular volume), azoospermia
(<8% of Klinefelter patients have few sperm in their ejacu-
late), markedly increased gonadotropin levels (LH and
FSH), low serum testosterone concentrations (<12 nmol/l),
varying symptoms of hypogonadism (e.g., feminine body con-
stitution and/or gynaecomastia may be present).
The vast majority of Klinefelter patients are infertile due to
azoospermia. However, after the introduction of in vitro fertil-
ization with intracytoplasmic sperm injection (ICSI), Klinefel-
ter men have a chance to become fathers. Recent studies report
high success rates of 30–70% for spermatozoa yields for ICSI
by using testicular sperm extraction (TESE) with special
microsurgical techniques locating focal spermatogenesis (12–
17). Therefore, the possibility of testicular biopsy/TESE and
cryopreservation of tissue should be discussed upon the first
diagnosis of Klinefelter syndrome, even without an expressed
wish for conception at the time (4).
1.1.3. Y-chromosomal microdeletions
Patients with non-obstructive azoospermia or severe oligozoo-
spermia should be investigated for the occurrence of microde-
letions of the Y chromosome, which represent one of the few
well-recognized genetic causes of spermatogenetic failures
resulting in male infertility (18). The breaking points of
deletions are well-characterized and five main microdeletion
Table 1 Chromosomal abnormalities in infertile men (data
taken from Mau-Holzmann (7)).
Abnormal karyotypes of 169 azoospermic males (originally analysed
n = 1287)
47, XXY 67%
Gonadal mosaicism 10%
46, XX 7%
Reciprocal translocations 4%
Robertsonian translocations 2%
Other gonosomal abnormalities 9%
Other autosomal abnormalities 1%
Abnormal karyotypes of 134 oligozoospermic males (originally
analysed n = 1287)
Robertsonian translocations 35%
Reciprocal translocations 16%
47, XXY 12%
47, XYY 8%
Inversions 8%
Extra structurally abnormal chromosomes 7%
Other autosomal abnormalities 1%
Other gonosomal abnormalities 13%
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P5-distal P1 (AZFbc), P4-distal P1 (AZFbc) and b2/b4 (AZFc)
(Fig. 2) (20). It is well-established that microdeletions of the Y
chromosome occur in infertile but not in control men,
although the frequency differs remarkably between countries,
possibly depending on the selection criteria of the patients
and on the ethnic background (18). Microdeletions of the Y
chromosome are rare and the vast majority (<80%) are dele-
tions involving the AZFc region (4). In general, azoospermic
men have a higher prevalence of microdeletions than oligozoo-
spermic men (4). This is reflected by the semen parameters,
which show azoospermia in about half of the patients, and
only a few spermatozoa in the ejaculate occasionally present
in the other half (4). Repeated semen analysis may be useful
in such patients, as spermatozoa may occasionally appear in
the ejaculate and be used for ICSI. Complete deletions of
AZFa or AZFb are always associated with azoospermia. In
general, TESE is possible in patients with AZFc deletions with
a probability of recovering sperm of about 50%, but no spermFigure 2 Current model of Y chromosome microdeletioretrieval has been so far reported in patients with complete
AZFa or AZFb deletions. Therefore, performing molecular ge-
netic testing in these patients has a definite prognostic value for
TESE. There are no clinical parameters beyond azoozpermia
or severe oligozoospermia that can be used to predict the
occurrence of a microdeletion of the Y chromosome (18). A
progressive deterioration of spermatogenesis in patients with
AZFc deletions has been proposed but never demonstrated
(18,21).
1.1.4. Congenital bilateral absence of the vas deferens
Patients with obstructive azoospermia are candidates for ge-
netic testing of mutations of the CFTR gene as they may have
a congenital malformation of the Wolffian ducts, which are the
precursors of the vas deferens, epididymis and seminal vesicles
during foetal development (4). Thus, hypo- or aplasia of the
epididymis or seminal vesicles can accompany the congenital
absence of the vas deferens (CBAVD). In contrast to men with
Y microdeletions, patients with CBAVD exhibit the distinct
clinical features of azoospermia, decreased seminal volume,
pH and markers of epididymal (a-glucosidase) and seminal
vesicle (fructose) function in the presence of normal luteinizing
hormone (LH), follicle-stimulating hormone (FSH) and testos-
terone levels.
In the majority of men with CBAVD, normal spermatogen-
esis will be found on testicular biopsy with histological evalu-
ation/TESE, which also confirms the diagnosis of obstructive
azoospermia, and thus these men have a high chance of father-
ing a child by ICSI (4). However, the risk of a child having cys-
tic fibrosis (CF) is increased in comparison with the general
population and can be estimated depending on the CFTR
mutation(s) of the man and the carrier status of the female
partner, as CF is inherited in an autosomal-recessive manner.
1.1.5. Hypogonadotropic hypogonadism
Hypogonadotropic hypogonadism (HH) is defined as a clinical
syndrome characterized by low sex steroid and low gonadotro-
pin levels resulting from a defect in the normal pulsatile secre-
tion pattern of GnRH from the hypothalamus. Clinically, HH
can be present with or without anosmia, the latter known as
Kallmann’s syndrome (22,23). Mutations of genes involved
in the migration and/or function of the GnRH-secretingn pattern [from Repping et al. (19) with permission].
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and, more rarely, in sporadic cases (4). The first gene identified
to be responsible for this phenotype was denominated KAL1
and encodes for a protein of the extracellular matrix, anos-
min-1. Successively, more genes were found to be mutated in
HH with or without anosmia (Table 2).
The search for mutations in the genes involved in HH with
or without anosmia requires direct gene sequencing or
sequencing after mutation screening by melting curve technol-
ogy or an equivalent method (4). As these techniques are
demanding in terms of time and resources, mutational analysis
should be performed after careful genetic counselling, which
allows full definition of the symptoms, identification of the
familial cases and definition of the pattern of inheritance
(autosomal-dominant, autosomal-recessive or X-linked),
thereby limiting the number of genes to be screened.
1.1.6. Idiopathic infertility
Chromosomal anomalies are found in about 7% men with idi-
opathic spermatogenic failure, predominantly numerical/struc-
tural in azoospermic men and translocations/inversions in
oligospermic men (24). Routine karyotyping of men with
sperm densities less than 10 million/ml, even in the absence
of other clinical presentations, is recommended because infer-
tility is associated with higher rates of aneuploidy in ejaculated
or testicular sperm and increased chromosomal defects in ICSI
offspring (24). When AZF-deleted sperm are available and
used for ICSI, fertility defects on male offspring seem inevita-
ble (24). Genetic causes of idiopathic infertility must be sought
by systematic valuation of infertile men and affected couples
must be informed about the implications of such diagnosis
for assisted reproductive technology outcome and their poten-
tial offspring. There is currently no indication for individual
gene analysis in idiopathic infertility (4).
1.2. Female infertility
Some major causes underlying female infertility are polycystic
ovary syndrome (PCOS), premature ovarian failure (POF) and
recurrent pregnancy loss (RPL).
1.2.1. Polycystic ovary syndrome
According to the Rotterdam criteria two of the following have
to be met in order to fit the definition of PCOS: chronic oligo-/Table 2 Genes mutated in Isolated Hypogonadotropic Hypogonad
Acronym Name Location
GNRHR Gonadotropin-releasing hormone receptor 4q21.2
KISS1 KiSS-1 metastasis-suppressor (metastin) 1q32
GPR54 G protein-coupled receptor 54 19p13.3
KAL1 Kallmann syndrome 1 sequence (anosmin-1) Xp22.32
FGFR1 Fibroblast growth factor receptor 1 8p11.2–p11.1
FGF8 Ffibroblast growth factor 8 10q24
PRKR2 Prokineticin receptor 2 20p12.3
PRK2 Prokineticin 2 3p13
CHD7 Chromodomain helicase DNA binding protein 7 8q12.2
GnRH1 Gonadotropin-releasing hormone 8p21 p11.2anovulation, clinical and/or biochemical evidence of hyperan-
drogenism, and polycystic ovaries (25). As the PCOS consists
in a set of symptoms, biochemical features, and signs that
can occur in various combinations, it can also be associated
with features of the metabolic syndrome including insulin
resistance and obesity, with a 7-fold increased risk of develop-
ing type 2 diabetes (26). As a result of these possible associa-
tions the clinical expression of the syndrome varies.
Several genes controlling ovarian function and metabolism
are associated with increased susceptibility to PCOS, but none
is strong enough to correlate alone with susceptibility to the dis-
ease, or response to therapy. A large number of studies have
investigated polymorphisms in the gene encoding the receptor
for FSH (FSHR). Only one single nucleotide polymorphism
(SNP) in exon 10 of the FSHR gene, FSHR p.N680S, was con-
sistently identified as having a significant association with ovar-
ian response to FSH, but it does not seem to play any major
role in the PCOS (27). The amount of FSH needed for con-
trolled ovarian hyperstimulation to achieve similar peek estra-
diol levels was significantly lower in women with the N/N
genotype at position 680 of the FSHR gene compared with wo-
men carrying the S/S genotype or N/S genotype, indicating low-
er ovarian sensitivity to FSH in vivo for the S680 allele (28).
Both inactivating and activating FSHR mutations may lead
to relevant clinical effects. Inactivating mutations can result in
primary or secondary amenorrhea, infertility and premature
ovarian failure (POF), while activating mutations can predis-
pose to ovarian hyperstimulation syndrome (OHSS) as a con-
sequence of exogenous FSH administration or even with a
spontaneous onset (29). If the effects of FSHR gene mutations
and polymorphisms on reproductive pathologies are studied
further, interesting scenarios for the clinical application of
gene sequencing in well-defined conditions could be opened
in the near future. Two examples thereof are the precocious
identification of women at risk of POF and the possibility of
‘‘tailoring’’ controlled ovarian stimulation in IVF with an
FSH stimulation schedule based on the individual responsive-
ness of FSHR (29). Besides the influence of FSHR genotype on
ovarian responsiveness, other genetic factors have been ana-
lysed and reported to be involved in modulating the ovarian
sensitivity to FSH. Among candidate genes we can mention
the ER1 (30–32) and ER2 genes (32), as well as the anti-Mu¨lle-
rian hormone (AMH) and AMH type II receptor genes (33)
and the MTHFR (methylenetetrahydrofolate reductase)ism and in Kallmann syndrome (4).
Gene ID Function
2798 Receptor for the gonadotropin-releasing hormone
3814 Ligand of GPR54: stimulation of GnRH secretion
84634 Receptor for Kiss-1: stimulation of GnRH secretion
3730 Possible function in neural cell adhesion and axonal
migration
2260 Binds both acidic and basic fibroblast growth factors
2253 Member of the fibroblast growth factor (FGF) family
involved in organogenesis
128674 G protein-coupled receptor for prokineticins
60675 Chemoattractant for neuronal precursor cells in the
olfactory bulb
55636 Expressed in undifferentiated neuroepithelium and in
mesenchyme of neural crest origin
2796 Stimulation of LH and FSH secretion
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morphisms in genes encoding for metabolic enzymes on ovar-
ian response such as the CYP19A1 gene and the BMP15 gene.
As ovarian responsiveness to FSH may be a polygenic trait,
the combined role of all these factors needs further investiga-
tion through large number and well-designed studies on pa-
tients undergoing ovarian hyperstimulation before drawing
conclusions about the effects of these various genotypes on
the ovarian response to the FSH (27).
1.2.2. Recurrent pregnancy loss
RPL, occurring in 0.5–1% of total pregnancies, is defined as
three or more consecutive spontaneous abortions before
20 weeks of gestation. Although an immunology-based aetiol-
ogy underlying unexplained RPL has been demonstrated, the
exact molecular and genetic mechanisms are still poorly under-
stood. Recent studies showed that particular immunological
abnormalities and thrombophilic aberration might underlie
RPL. Approximately 25–51% of miscarriages in women with
RPL are associated with a chromosomal abnormality in the
conceptus (36–39), and karyotyping of abortuses should be
performed to determine whether there is a cytogenetic reason
for the loss (39).
Based on equal frequencies of abnormal test results found
among patients with two, three or four or more recurrent preg-
nancy losses, Jaslow et al. (40) suggests that a complete evalu-
ation of evidence-based factors, i.e., parental karyotyping,
uterine anatomy, lupus anticoagulant, anticardiolipin antibod-
ies, factor V Leiden, and TSH should be recommended to all
couples with two or more consecutive pregnancy losses (40).
Caution must be exerted in the interpretation of an abnormal
screening result, as the factor identified may not be the causa-
tive factor for pregnancy loss.
1.2.3. Premature ovarian failure
POF is another condition thought to be genetically deter-
mined. It is defined as a primary ovarian defect characterized
by absent menarche (primary amenorrhea) or premature
depletion of ovarian follicles/arrested folliculogenesis before
the age of 40 years (secondary amenorrhea) (41,42).
The causes of POF are extremely heterogeneous. Karyotype
analyses should be performed in primary amenorrhea and in
cases of POF at very young age. Mutations of several genes
effecting hormone action and follicle function (FSH, FSHR,
LH, LHR, CYP17, CYP19, BMP15, GDF9, and GPR3) have
been occasionally found in humans, but none are common.
Other genes such as DNA binding proteins and transcription
factors like NOBOX and LHX8, and RNA binding proteins
like NANOS are involved in oogenesis. Plausible causative
mutations have been identified in a few women (NOBOX,
GDF9, and LHX8), but are exceedingly rare (only 1–2% of
cases). Thus, considerable heterogeneity exists in POF and
no routine genetic screening can be recommended so far be-
yond karyotype. Two of the candidate genes are located on
the X chromosome. FMR1 gene (Xq27.3) mutations or pre-
mutations are typically associated with secondary amenorrhea
in female relatives of male patients with mental retardation
(43). A significant risk of POF is represented by a premutation
of fewer than 100 CGG repeats in female carriers of fragile X
syndrome (44). BMP15 gene (Xq11.2) defect has so far been
described in two sisters with primary amenorrhea and hetero-
zygous for the mutation. This defect would represent an unu-sual example of an X-linked disease in which affected females
inherit the mutation from their unaffected father (45) but has
been questioned by others (46).
An opportunity to predict the likelihood of early meno-
pause could be offered by an early diagnosis of familial
POF, which could also allow considering different reproduc-
tive choices, such as freezing embryos or having children ear-
lier. It is important for clinicians to make a timely diagnosis
and begin appropriate strategies for symptom management,
emotional support, and risk reduction, because POF has
cumulative negative effects over time (47). Karyotype evalua-
tion and other cytogenetic investigations are useful to identify
major X chromosome abnormalities.
Recently, Aboura et al. (48) identified 31 copy number vari-
ations (CNVs), using array comparative genomic hybridiza-
tion (a-CGH) analysis in a cohort of patients with POF.
Three CNVs were identified on the X chromosome and 28
on autosomal chromosomes. Eight of thirty-one CNVs re-
ported resulted statistically significant although no correlation
could be made between the CNVs and the phenotype of POF.
Genetic counselling is recommended for several reasons,
when a genetic form of POF is suspected or identified. Coun-
selling is of particular importance in cases of families with X-
linked mental retardation (Fragile X syndrome). The expan-
sion of CGG repeats is associated with gene silencing resulting
in male mental retardation and in POF with secondary amen-
orrhea in female carriers (44). When a female is born from a
family with other female members affected with POF, genetic
investigations may be useful for the early diagnosis of genetic
defects underlying POF. Pedigree studies on affected families
showed a mode of inheritance suggestive of autosomal domi-
nant sex-limited transmission or X-linked inheritance with
incomplete penetrance (47).2. Conclusions
Depending on the clinical findings, the infertile male patient
needs genetic evaluation. Karyotype analysis and Y-chromo-
somal microdeletion screening should be performed in patients
with azoospermia or severe oligozoospermia in order to rule
out structural chromosomal abnormalities, Klinefelter syn-
drome and Y chromosome microdeletions. Infertile patients
with obstructive azoospermia need CFTR gene screening,
while in patients with HH mutation screening may be per-
formed according to clinical features. All genetic analysis
should be accompanied by expert counseling by a clinical
genetist both in male and female patients (4).
Primary amenorrhea should be investigated by karyotype
analysis and selected mutation screening according to the pa-
tient’s clinical features. Karyotype analysis and FMR1 gene
screening is recommended in cases of POF. At present the
infertility of patients with POF cannot be restored if the diag-
nosis is made after complete follicular depletion, but in some
cases, early diagnosis by genetic investigation may instead lead
to the advice of early conception or oocyte harvesting and
preservation. In addition, the accumulation and annotation
of array CGH data might, in the near future, lead to the iden-
tification of pathogenetic CNVs and genes involved in POF
(48). Karyotype analysis of both partners is recommended in
all couples with RPL (49). No routine genetic test can be rec-
ommended so far in patients with PCOS.
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